Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: A needle-free vaccination strategy

Vicente, Sara; Peleteiro, Mercedes; Díaz-Freitas, Belén; Sánchez, Alejandro; González-Fernández, África; Alonso, Marı́a José

doi:10.1016/j.jconrel.2013.09.012

Cited by 73 publications

(74 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With ovalbumin as a model antigen, Kobayashi et al studied the safety and effectiveness of chitosan and its derivatives as mucosal adjuvants via the intranasal route in BALB/c mice, polymeric Ig receptor knockout (pIgR-KO) mice, and cynomolgus monkeys ( Macaca fascicularis ) [114]. Vicente et al also showed that chitosan nanocapsule co-delivery system with hepatitis B surface antigen induced balanced humoral and cellular immune responses in mice after intranasal vaccination [115]. Lubben et al used chitosan microparticles for oral delivery of diphtheria toxin (DT) and demonstrated induction of serum IgG equivalent to the intramuscular injection, and additionally, sIgA in fecal matter [116].…”

Section: Mucosal Vaccine Delivery Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Mucosal vaccine delivery: Current state and a pediatric perspective

Shakya

Chowdhury

Tao

et al. 2016

Journal of Controlled Release

127

115

View full text Add to dashboard Cite

Most childhood infections occur via the mucosal surfaces, however, parenterally delivered vaccines are unable to induce protective immunity at these surfaces. In contrast, delivery of vaccines via the mucosal routes can allow antigens to interact with the mucosa-associated lymphoid tissue (MALT) to induce both mucosal and systemic immunity. The induced mucosal immunity can neutralize the pathogen on the mucosal surface before it can cause infection. In addition to reinforcing the defense at mucosal surfaces, mucosal vaccination is also expected to be needle-free, which can eliminate pain and the fear of vaccination. Thus, mucosal vaccination is highly appealing, especially for the pediatric population. However, vaccine delivery across mucosal surfaces is challenging because of the different barriers that naturally exist at the various mucosal surfaces to keep the pathogens out. There have been significant developments in delivery systems for mucosal vaccination. In this review we provide an introduction to the MALT, highlight barriers to vaccine delivery at different mucosal surfaces, discuss different approaches that have been investigated for vaccine delivery across mucosal surfaces, and concludes with an assessment of perspectives for mucosal vaccination in the context of the pediatric population.

show abstract

Section: Mucosal Vaccine Delivery Systemsmentioning

confidence: 99%

“…Even TLR7/8 agonists, the imidazoquinolines, such as imiquimod or gardiquimod, have been shown to induce mucosal immune responses when co-delivered with hepatitis B surface antigen in chitosan nanocapsules upon intranasal vaccination in mice [115]. …”

Section: Adjuvants For Mucosal Routesmentioning

confidence: 99%

Mucosal vaccine delivery: Current state and a pediatric perspective

Shakya

Chowdhury

Tao

et al. 2016

Journal of Controlled Release

127

115

View full text Add to dashboard Cite

show abstract

“…For example, CS nanocapsules containing the antigen associated to the CS shell have been reported as useful carriers for the nasal delivery of the model antigen, ovalbumin 127 and also the recombinant hepatitis B surface antigen (rHBsAg). [168][169] Trimethyl CS based nanocarriers have also yielded promising results regarding nasal antigen delivery. Ovalbumin conjugated to TMC nanocarriers induced a marked increase in the IgG response when compared to a TMC ovalbumin solution.…”

Section: Nasal Drug/antigen Deliverymentioning

confidence: 99%

Polysaccharide-Based Nanocarriers for Drug Delivery

Teijeiro¹,

McGlone²,

Csaba³

et al. 2014

Frontiers in Nanobiomedical Research

Self Cite

View full text Add to dashboard Cite

“…In this regard, we combined the mucoadhesive properties of chitosan with the adjuvants squalene and imiquimod (TLR7/8 agonist). The results of the intranasal administration of this system showed that the co-encapsulation of antigen and adjuvants was key to generate enhanced and long-lasting IgG levels [174]. More recently, a layer-by-layer approach was evaluated to encapsulate the rHBsAg.…”

Section: The Potential Of Nanotechnology For Vaccinationmentioning

confidence: 99%

Modulating the immune system through nanotechnology

Dacoba

Ana

Torres

et al. 2017

Seminars in Immunology

107

View full text Add to dashboard Cite

Nowadays, nanotechnology-based modulation of the immune system is presented as a cutting-edge strategy, which may lead to significant improvements in the treatment of severe diseases. In particular, efforts have been focused on the development of nanotechnology-based vaccines, which could be used for immunization or generation of tolerance. In this review, we highlight how different immune responses can be elicited by tuning nanosystems properties. In addition, we discuss specific formulation approaches designed for the development of anti-infectious and anti-autoimmune vaccines, as well as those intended to prevent the formation of antibodies against biologicals.

show abstract

Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: A needle-free vaccination strategy

Cited by 73 publications

References 40 publications

Mucosal vaccine delivery: Current state and a pediatric perspective

Mucosal vaccine delivery: Current state and a pediatric perspective

Polysaccharide-Based Nanocarriers for Drug Delivery

Modulating the immune system through nanotechnology

Contact Info

Product

Resources

About